Ibogaine in the treatment of chronic hepatitis C Howard S. Lotsof. President Dora Weiner Foundation Staten Island, NY  htt...
Forms of ibogaine  in current use <ul><li>•  Botanical - root bark </li></ul><ul><li>•  Total alkaloid extract </li></ul><...
Tabernanthe iboga shrub
Roots contain ibogaine
Total Alkaloid Extract Large piece 2cm x 2cm, approx 4 grams Estimate 15% ibogaine Courtesy Sara Glatt
Ibogaine HCl 99.4% purity
Hepatitis C (HCV) timeline 1973: Non A, Non B hepatitis is described 1989: HCV RNA virus identified 1990: Anti HCV effects...
HCV infection Most common viral infection in the  United States New infections per year 1990 - 242,000 New infections per ...
Science follows  patent development <ul><li>The discovery of ibogaine’s use in treating both chemical dependence and HCV w...
Ibogaine Patents <ul><li>Rapid method for interrupting the  narcotic addiction  syndrome, US 4,499,096 (1985) </li></ul><u...
Research follows skepticism <ul><li>Broad ranging claims of ibogaine to treat multiple forms of chemical dependence doubte...
Opioids
Cocaine
Alcohol
Nicotine
Ibogaine activist  organizations play role in ibogaine HCV research <ul><li>International Coalition for Addict Self-Help (...
HCV patent application
Example 1  Report A thirty-three year old male diagnosed with HCV and using 1/4 gram of heroin a day was administered 25 m...
Example 2  Liver enzyme values reduced  by 14 mg/kg ibogaine Enzyme Pre Post ALT 410 50 AST 201 25 GGT 155 33
Example 3
Example. 4  A forty-two year old female testing positive for HCV RNA type 3.  RNA IU/ml was 12,600,000. Subject was admini...
Encouraging results <ul><li>Repetitive low dosing with ibogaine provided continuous depression of viral load. </li></ul><u...
Future development <ul><li>Interest of pharmaceutical companies with experience in development of HCV drugs. </li></ul><ul...
Upcoming SlideShare
Loading in …5
×

Ibogaine in the Treatment of Chronic Hepatitis C

2,531 views

Published on

Published in: Health & Medicine
0 Comments
2 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
2,531
On SlideShare
0
From Embeds
0
Number of Embeds
59
Actions
Shares
0
Downloads
25
Comments
0
Likes
2
Embeds 0
No embeds

No notes for slide
  • Workshop participants will be asked if they have a copy of the manual. If everyone has a copy, fine. If not, those who do not want the manual will be asked to give their copy to someone who wants a copy.
  • Ibogaine in the Treatment of Chronic Hepatitis C

    1. 1. Ibogaine in the treatment of chronic hepatitis C Howard S. Lotsof. President Dora Weiner Foundation Staten Island, NY http://www.doraweiner.org 6th National Conference on Harm Reduction Oakland, California, November 2006
    2. 2. Forms of ibogaine in current use <ul><li>• Botanical - root bark </li></ul><ul><li>• Total alkaloid extract </li></ul><ul><li>• purified ibogaine </li></ul>
    3. 3. Tabernanthe iboga shrub
    4. 4. Roots contain ibogaine
    5. 5. Total Alkaloid Extract Large piece 2cm x 2cm, approx 4 grams Estimate 15% ibogaine Courtesy Sara Glatt
    6. 6. Ibogaine HCl 99.4% purity
    7. 7. Hepatitis C (HCV) timeline 1973: Non A, Non B hepatitis is described 1989: HCV RNA virus identified 1990: Anti HCV effects of ibogaine reported 2005: Patent application for ibogaine to treat chronic HCV
    8. 8. HCV infection Most common viral infection in the United States New infections per year 1990 - 242,000 New infections per year 2001 - 25,000 New infections per year 2004 - 25,000 Greater than 75% of IVDUs test positive
    9. 9. Science follows patent development <ul><li>The discovery of ibogaine’s use in treating both chemical dependence and HCV was by ibogaine activist advocates who were themselves treated or self-treated with ibogaine. </li></ul><ul><li>Scientific research followed patent development in the treatment of chemical dependence and it is hoped the same will be true for ibogaine related HCV research. </li></ul>
    10. 10. Ibogaine Patents <ul><li>Rapid method for interrupting the narcotic addiction syndrome, US 4,499,096 (1985) </li></ul><ul><li>Rapid method for interrupting the cocaine and amphetamine abuse syndrome US 4,587,243 (1986) </li></ul><ul><li>Rapid method for attenuating the alcohol dependency syndrome, US 4,957,523 (1989) </li></ul><ul><li>Rapid method for interrupting or attenuating the nicotine/tobacco dependency syndrome, US 5,026,697 (1991) </li></ul><ul><li>Rapid method for interrupting or attenuating poly-drug dependency syndromes, US 5, 124,994 (1992) </li></ul>
    11. 11. Research follows skepticism <ul><li>Broad ranging claims of ibogaine to treat multiple forms of chemical dependence doubted </li></ul><ul><li>Over time, all claims for treating chemical dependence have been confirmed by research </li></ul><ul><ul><ul><li>Opioids, </li></ul></ul></ul><ul><ul><ul><li>stimulants, </li></ul></ul></ul><ul><ul><ul><li>Alcohol </li></ul></ul></ul><ul><ul><ul><li>nicotine </li></ul></ul></ul>
    12. 12. Opioids
    13. 13. Cocaine
    14. 14. Alcohol
    15. 15. Nicotine
    16. 16. Ibogaine activist organizations play role in ibogaine HCV research <ul><li>International Coalition for Addict Self-Help (ICASH) 1989 </li></ul><ul><li>Dutch Addict Self-Help (DASH) 1990 </li></ul><ul><li>Ibogaine Underground 2004 </li></ul>
    17. 17. HCV patent application
    18. 18. Example 1 Report A thirty-three year old male diagnosed with HCV and using 1/4 gram of heroin a day was administered 25 mg/kg ibogaine HCl. Following administration of ibogaine heroin use ceased along with swelling of the liver and pain in the area of the liver.
    19. 19. Example 2 Liver enzyme values reduced by 14 mg/kg ibogaine Enzyme Pre Post ALT 410 50 AST 201 25 GGT 155 33
    20. 20. Example 3
    21. 21. Example. 4 A forty-two year old female testing positive for HCV RNA type 3. RNA IU/ml was 12,600,000. Subject was administered a total of 27 mg/kg ibogaine HCl in the following regimen: 6 x 2 mg/kg 1 x 12 mg/kg 1 x 3 mg/kg HCV RNA IU/ml was reduced to 50,100. Prior to ibogaine treatment patient’s urine was dark and stool light. Post treatment color of urine and stool returned to normal.
    22. 22. Encouraging results <ul><li>Repetitive low dosing with ibogaine provided continuous depression of viral load. </li></ul><ul><li>Genotype 3 appears highly responsive in keeping with results of interferon riboviron therapy. </li></ul><ul><li>Continued reduction in viral load after stopping of ibogaine therapy observed. </li></ul><ul><li>Less toxic than current HCV therapies. </li></ul>
    23. 23. Future development <ul><li>Interest of pharmaceutical companies with experience in development of HCV drugs. </li></ul><ul><li>Preclinical confirmation of efficacy if possible. </li></ul><ul><li>Phase I/II clinical studies to confirm findings and establish preferred dose regimen. </li></ul>

    ×